

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 September 2010 (23.09.2010)

(10) International Publication Number
WO 2010/108179 A1

PCT

(51) International Patent Classification:
G01N 33/53 (2006.01)

(21) International Application Number:
PCT/US2010/028155

(22) International Filing Date:
22 March 2010 (22.03.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/162,225 20 March 2009 (20.03.2009) US

(71) Applicant (for all designated States except US): **THE SALK INSTITUTE FOR BIOLOGICAL STUDIES** [US/US]; 10010 North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EVANS, Ronald** [US/US]; 1471 Cottontail Lane, La Jolla, CA 92037 (US). **LAMIA, Katja A.** [US/US]; 12636 Ragweed Street, San Diego, CA 92129 (US). **SHAW, Reuben J.** [US/US]; 12636 Ragweed Street, San Diego, CA 92129 (US). **DI-TACCHIO, Luciano** [US/US]; 9134 Regents Road Apt. A, La Jolla, CA 92037 (US). **PANDA, Satchidananda** [IN/US]; 7615 Norcanyon Way, San Diego, CA 92126

(US). **SACHDEVA, Uma M.** [US/US]; 715 N. Ithan Avenue, Rosemont, PA 19010 (US). **THOMPSON, Craig, B.** [US/US]; 304 Mallwyd Road, Merion, PA 19066 (US).


(74) Agent: **BAKER, Jr., Joseph R.**; Gavrilovich, Dodd & Lindsey, LLP, 4660 La Jolla Village Drive, Suite 750, San Diego, CA 92122 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM,

[Continued on next page]

(54) Title: METHODS FOR MODULATING CIRCADIAN RHYTHMS



(57) Abstract: This disclosure described the role of AMPK in circadian rhythms and methods of screening for agents that modulate such rhythms, compositions that are useful for modulating such rhythms and uses thereof.

WO 2010/108179 A1



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, **Published:**
ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*

METHODS FOR MODULATING CIRCADIAN RYTHMS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of US Provisional Application No. 61/162,225, filed March 20, 2009, herein incorporated by reference.

ACKNOWLEDGEMENT OF GOVERNMENT SUPPORT

[0002] This work was supported by National Institutes of Health Grant Nos. DK057978, DK062434, CA104838, DK080425, and EY016807. The Government of the United States has certain rights in this invention.

FIELD OF THE INVENTION

[0003] This disclosure concerns the use of agonists and antagonists of AMP-activated protein kinase (AMPK) for modulating circadian rhythms. More particularly, the disclosure provides compositions and methods for screening and modulating sleep behavior.

BACKGROUND

[0004] Circadian clocks coordinate behavioral and physiological processes with daily light-dark cycles by driving rhythmic transcription of thousands of genes in mammalian tissues.

SUMMARY

[0005] The disclosure provides methods and compositions for modifying circadian rhythms in a mammalian subject such as a human. The disclosure demonstrates that AMPK is modified during the circadian cycle of mammalian subjects both in the brain and in other tissues in the body. In one embodiment, the disclosure provides the use of an AMP kinase agonist or antagonist for the manufacture of a medicament to modulate circadian rhythms in a subject. In one embodiment, the AMPK agonist is AICAR. In another embodiment, the AMPK antagonist is an antibody or a compound C or analog or derivative thereof. In yet another embodiment, the AMPK agonist comprises a formulation or derivation that is capable of crossing the blood brain barrier. In yet a further embodiment, the AMPK agonist is formulated for oral administration, intravenous injection, intramuscular injection, epidural delivery, intracranial or subcutaneous injection.

[0006] The disclosure also provides a composition comprising an AMPK agonist formulated in combination with a second active ingredient that modifies circadian rhythms. In one embodiment, the second active ingredient is a sleep aid. In a further embodiment, the composition is formulated for oral administration, intravenous injection, intramuscular injection, epidural delivery, intracranial delivery, or subcutaneous injection.

[0007] The disclosure provides a method for modulating sleep in a mammal comprising, administering to the mammal an effective amount of an AMPK agonist or antagonist to modulate circadian rhythms in a mammal.

[0008] The disclosure also provides a method for identifying an agent that modulates circadian rhythms or sleep in a subject, comprising: (a) contacting a sample comprising a AMPK pathway with at least one test agent; and (b) comparing an activity of the AMPK or AMPK pathway in the presence and absence of the test agent wherein a test agent the changes that activity is indicative of an agent that circadian rhythm modulating activity.

[0009] The foregoing and other features will become more apparent from the following detailed description of several embodiments, which proceeds with reference to the accompanying figures.

BRIEF DESCRIPTION OF THE FIGURES

[0010] FIG. 1A-D shows disruption of AMPK signaling alters circadian rhythms in MEFs. (A) Unsynchronized paired wild type (AMPK^{+/+}) or *ampkα1*^{-/-}; *ampkα2*^{-/-} (AMPK^{-/-}) mouse embryonic fibroblasts were stimulated by 2 hour exposure to 50% horse serum followed by transfer to media containing 25 mM glucose, 0.5 mM glucose or 25 mM glucose supplemented with 1 mM AICAR. Quantitative PCR analysis was performed using cDNA samples collected at the indicated times following stimulation. Data represent the mean of two independent experiments, each analyzed in triplicate. (B) Fibroblasts stably expressing *Bmal1-luciferase* were cultured in media containing the indicated amounts of glucose with or without 2 mM AICAR. Typical results of continuous monitoring of luciferase activity are shown. (C and D)

Quantitation of the circadian period (C) and amplitude (D) of *Bmal1*-driven luciferase activity from experiments performed as described in (B). Data in (C) and (D) represent the mean \pm standard deviation for four samples per condition. ANOVA analysis indicated a significant difference between categories. ** $P < 0.01$ vs. samples cultured in 25 mM glucose in Scheffe's post-hoc analysis.

[0011] FIG. 2A-C shows AMPK activity and nuclear localization undergo circadian regulation. (A) Immunoblotting for phospho-Raptor-S792 (pRaptor), Raptor, phospho-ACC1-S79 (pACC1) and ACC1 were performed in whole cell lysates prepared from mouse livers collected at the indicated circadian times. The blots are representative of three independent experiments. (B) Quantitative PCR analysis of cDNA prepared from mouse livers collected at the indicated circadian times. Each data point represents the mean \pm standard deviation of three samples each taken from a unique animal and analyzed in quadruplicate. (C) Nuclear extracts were prepared from the livers of two mice at each of the indicated circadian times. Protein levels of AMPK α 1, AMPK α 2, PER2, CRY1 and REVERB α were analyzed by immunoblotting. Nuclear extracts from paired wild type (α 1+/+) and *ampk α 1*^{-/-} (α 1-/-) or wild type (α 2+/+) and *ampk α 2*^{-/-} (α 2-/-) mice collected at the indicated circadian times were used as controls for antibody specificity.

[0012] FIG. 3A-C shows AMPK activation alters CRY stability and circadian rhythms in mouse livers. (A) Mice were injected with saline or 500 mg AICAR per kg of bodyweight and liver samples were collected one hour later at zeitgeber time (ZT, hours after lights on) 6 or ZT18. Endogenous CRY1 was detected by immunoblotting in liver nuclear extracts. n.s. denotes a non-specific band to assess sample load. Samples collected from wild type (CRY+/+) and *cry1*^{-/-}; *cry2*^{-/-} (CRY^{-/-}) mice were used as controls for antibody specificity. Data represents a typical result from two independent experiments. (B) LKB1^{+/+} and LKB1^{Δ1/Δ1} mice were injected with adenovirus expressing Cre recombinase (Ad-Cre) via the tail vein. One to two weeks after Ad-Cre injection, mice were transferred to constant darkness and livers were collected at the indicated

circadian times. CRY1, PER2, and REVERB α , were detected by immunoblotting. (C) cDNA samples prepared from the livers described in (B) were analyzed by quantitative PCR analysis of *dbp*, *reverb α* , *cry1*, and *per2* expression. All transcripts were normalized to *u36b4* as an internal control. Each data point represents the mean \pm standard deviation of three samples analyzed in quadruplicate.

[0013] Fig. 4A-B show disruption of AMPK alters circadian rhythms in MEFs. 3T3 immortalized mouse embryonic fibroblasts (A) or paired wild type (AMPK^{+/+}) or *ampk α 1^{-/-};ampk α 2^{-/-}* (AMPK^{-/-}) fibroblasts (B) were stimulated by 2 hour exposure to 50% horse serum followed by transfer to media containing 25 mM glucose (black symbols), 0.5 mM glucose (gray symbols) or 25 mM glucose supplemented with 1 mM AICAR (red symbols). Quantitative PCR analysis was performed using cDNA samples prepared from lysates collected at the indicated times following stimulation. Data represent the mean \pm standard deviation of two or three independent experiments each analyzed in triplicate.

DETAILED DESCRIPTION

[0014] Unless specifically noted otherwise herein, the definitions of the terms used are standard definitions used in the art of pharmaceutical sciences. As used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pharmaceutical carrier" includes mixtures of two or more such carriers, and the like.

[0015] Also, the use of "or" means "and/or" unless stated otherwise. Similarly, "comprise," "comprises," "comprising" "include," "includes," and "including" are interchangeable and not intended to be limiting.

[0016] It is to be further understood that where descriptions of various embodiments use the term "comprising," those skilled in the art would understand that in some specific instances, an embodiment can be alternatively described using language "consisting essentially of" or "consisting of."

[0017] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. Although any methods and reagents similar or equivalent to those described herein can be used in the practice of the disclosed methods and compositions, the exemplary methods and materials are now described.

[0018] All publications mentioned herein are incorporated herein by reference in full for the purpose of describing and disclosing the methodologies, which are described in the publications, which might be used in connection with the description herein. The publications discussed above and throughout the text are provided solely for their disclosure prior to the filing date of the disclosure. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior disclosure.

[0019] Circadian rhythms optimize biological efficiency by coordinating appropriate timing of physiological, endocrine and behavioural processes, such as, without limitation, modulation of sleep cycles, energy modulation associated with exercise and calorie reduction, and feeding/nourishment behaviours. Circadian rhythms are thought to contain at least three elements: (a) input pathways(s) that relay environmental information to a circadian pacemaker (clock); (b) a circadian pacemaker that generates the oscillation; and (c) output pathway(s) through which the pacemaker regulates various output rhythms.

[0020] The mammalian hypothalamic suprachiasmatic nucleus (SCN) acts as a master pacemaker aligning behavioral and physiological rhythms to light-dark cycles. Initially, the SCN was thought to be the only site of self-sustaining molecular pacemakers in mammals but multiple reports have subsequently shown that such molecular clocks are nearly ubiquitous. Unlike the SCN clock, circadian clocks in non-light sensitive peripheral organs are entrained by daily rhythms of feeding, theoretically allowing peripheral tissues to anticipate daily food consumption and to optimize the timing of metabolic processes. A number of reports support roles for

mammalian circadian clocks in regulating the transcription of key metabolic enzymes and in metabolic physiology.

[0021] As used herein, the term "circadian rhythm" is intended to mean the regular variation in physiologic and behavioral parameters that occur over the course of about 24 hours. Such activities include the sleep cycle and nourishment cycle, as well as others. In one embodiment, the circadian rhythm can include energy modulation associated exercise and calorie reduction. For example, the methods and compositions of the disclosure can be used to modulate energy use and sleep in the body. As described below, AMPK agonists induce a metabolic shift towards the generation of ATP by catabolism of fats, while simultaneously reducing ATP use by setting the body to a rest state. Accordingly, AMPK agonists can both induce an exercise catabolic/metabolic process as well as inducing a resting/sleep state.

[0022] As used herein, the term "modulating" when used in reference to circadian rhythm is intended to mean altering a physiological function, endocrine function or behavior that is regulated by the circadian timing system of an animal, or altering a cellular function that exhibits circadian rhythmicity. Exemplary physiological functions regulated by the circadian timing system of an animal include body temperature, autonomic regulation, metabolism, and sleep-wake cycles. Exemplary metabolic functions include control of weight gain and loss, including increase or decrease in body weight and increase or decrease in percent body fat. Exemplary endocrine functions regulated by the circadian timing system of an animal include pineal melatonin secretion, ACTH-cortisol secretion, thyroid stimulating hormone secretion, growth hormone secretion, neuropeptide Y secretion, serotonin secretion, insulin-like growth factor type I secretion, adrenocorticotrophic hormone secretion, prolactin secretion, gamma-aminobutyric acid secretion and catecholamine secretion. Exemplary behaviors regulated by the circadian timing system of an animal include movement (locomotor rhythm), mental alertness, memory, sensorimotor integration, feeding, REM sleep, NREM sleep and emotion.

[0023] The AMP-activated protein kinase (AMPK) has been recognized as a central mediator of metabolic signals that is well conserved throughout phylogeny. AMPK is a heterotrimeric protein kinase comprising a catalytic (α) subunit and two regulatory (β, γ) subunits. It is activated when it is phosphorylated by LKB1 in the presence of high AMP/ATP ratios or by CAMKK β in the presence of elevated intracellular calcium. Biochemical and bioinformatic studies have established the optimal amino acid sequence context in which phosphorylation by AMPK is likely.

[0024] AMP-activated protein kinase (AMPK) and AMPK kinase (AMPKK) are associated with a protein kinase cascade. The AMPK cascade regulates fuel production and utilization intracellularly. For example, low cellular fuel (e.g., an increase in AMP concentration) increase AMPK activity. Once activated, AMPK functions either to conserve ATP or to promote alternative methods of ATP generation.

[0025] AMPK is expressed in a number of tissues, including the liver, brain, and skeletal muscle. Activation of AMPK has been shown to activate hepatic fatty acid oxidation and ketogenesis, inhibit cholesterol synthesis, lipogenesis, and triglyceride synthesis, inhibit adipocyte lipolysis and lipogenesis, stimulate skeletal muscle fatty acid oxidation and muscle glucose uptake, and modulate insulin secretion by pancreatic beta-cells.

[0026] Triggering the activation of AMPK can be carried out with increasing concentrations of AMP. The γ subunit of AMPK undergoes a conformational change so as to expose the active site (Thr-172) on the α subunit. The conformational change of the γ subunit of AMPK can be accomplished under increased concentrations of AMP. Increased concentrations of AMP will give rise to the conformational change on the γ subunit of AMPK as two AMPs bind the two Bateman domains located on that subunit. This role of AMP is demonstrated in experiments that show AMPK activation via an AMP analogue 5-amino-4-imidazolecarboxamide ribotide (ZMP) which is derived from 5-amino-4-imidazolecarboxamide riboside (AICAR). Similarly, antagonists of AMP include the use of inhibitory

antibodies that inhibit the activation of downstream kinases by AMPK.

[0027] Sleep deprivation (SD) increases neuronal activity. Sustained neuronal activity decreases the cellular energy charge (AMP levels increase and ATP decrease). This in-turn causes a change in the cellular energy sensor AMPK. AMPK, as discussed above, modulates various kinase cascades.

[0028] CLOCK and BMAL1 are polypeptides that upon forming a heterodimer induce transcription of genes associated with circadian rhythms. During a typical circadian cycle, molecular mechanism oscillate between two cycles forming an internal clock having two interconnected transcription/translation feedback loops. The positive arm of the feedback loop is driven by a basic helix-loop-helix-PAS (Per-Arnt-Sim) domain-containing transcription factors CLOCK and BMAL1. The CLOCK/BMAL1 heterodimer activates transcription of the clock genes cryptochrome (Cry1 and Cry2), period (Per1 and Per2), and Rev-Erb α . PER and CRY proteins translocate to the nucleus, where they interact with CLOCK/BMAL1 to down-regulate transcription, generating the negative arm of the major feedback loop.

[0029] Posttranslational modification of clock proteins (e.g., phosphorylation and dephosphorylation) determines the protein's localization, intermolecular interactions, and stability and thus regulates the period of the circadian clock. The disclosure demonstrates that this posttranslational regulation can be modulated by AMPK activity and thus AMPK agonist and antagonist can play a role in regulating circadian clock.

[0030] The disclosure provide the use of compounds that bind to or otherwise activate or inactivate the AMP-activated protein kinase (AMPK), some of which are currently used for the treatment of diabetes, to influence sleep or other circadian processes. The disclosure demonstrates that genetic or pharmacological manipulation of AMP-activated protein kinase activity alters circadian rhythms in cultured cells and in the livers of intact animals. The disclosure also demonstrates that AMP kinase is expressed in the suprachiasmatic nucleus (SCN), the location of the

so-called "master pacemaker" that governs the timing of sleep-wake cycles and other physiological rhythms. Currently available therapies do not cross the blood brain barrier and would therefore not be useful for the modulation of sleep disorders.


[0031] The regulation of circadian rhythms by AMPK suggest that AMPK modulators that cross the blood brain barrier would be useful in the treatment of sleep disorders including, but not limited to, insomnia by regulating downstream kinase activity associated with circadian rhythms. In addition, certain circadian polypeptides including, but not limited to, CLOCK, BMAL1, PER and CRY-1 and -2 are regulated by phosphorylation and dephosphorylation and are present in tissues outside the brain. Accordingly, modulating AMPK activity in non-neurological tissue may also be important for setting a circadian rhythm through the kinase cascade and ultimately the regulation of downstream polypeptide phosphorylation and dephosphorylation.

[0032] A number of pharmacological agents that activate AMPK are currently in clinical use for the treatment of diabetes and are in clinical trials for some types of cancer.

[0033] AMP kinase agonists such as AICAR have been studied for insulin regulation, diabetes and obesity. However, AMP kinases have not previously been demonstrated to modulate circadian rhythms or sleep behavior. The disclosure demonstrates that modulating AMPK activity can have an effect on downstream processes including the posttranslational modification of proteins associated with circadian rhythms. In one embodiment, the disclosure provides that AMPK agonists and antagonists can be used to modulate circadian rhythm in a subject. For example, AMPK is demonstrated by the disclosure to play a role in the modulation of the transcription activating heterodimer CLOCK/BMAL1.

[0034] Various AMPK agonist are known in the art. Methods and compositions comprising such AMPK agonist are provided herein. The use of such AMPK agonist can provide methods for modulating circadian rhythms. In one embodiment, the AMPK agonist comprises an AICAR compound. Other compounds useful in the method of the disclosure include biguanide derivatives, analogs of AICAR (such as

those disclosed in U. S. Patent No. 5,777,100, hereby incorporated by reference herein) and prodrugs or precursors of AICAR (such as those disclosed in U. S. Patent No. 5,082,829, hereby incorporated by reference herein), which increase the bioavailability of AICAR, all of which are well-known to those of ordinary skill in the art. Other activators of AMPK include those described in U.S. Patent Publication No. 20060287356 to Iyengar *et al.* (the disclosure of which is incorporated herein by reference). Conventionally known AMPK-activating compounds include, for example, leptin, adiponectin, and metformin, AICAR (5-aminoimidazole-4-carboxamide). Other AMPK agonists include, but are not limited to, phenformin, ZMP, DRL-16536 (Dr. Reddy's/Perlecan Pharma), BG800 compounds (Betagenon), furan-2-carboxylic acid derivative (Hanall, KR; see also Int'l. Application Publ. WO/2008/016278, incorporated herein by reference), A-769662 (Abbott) (structure I; see also, Cool *et al.*, Cell Metabol. 3:403-416, 2006); AMPK agonist under development by Metabasis as set forth in Int'l. Publication No. WO/2006/033709; MT-39 series of compounds (Mercury Therapeutics); and AMPK agonist under development by TransTech Pharma:



(I)

[0035] AICAR, for example, is taken into the cell and converted to ZMP, an AMP analog that has been shown to activate AMPK. ZMP acts as an intracellular AMP mimic, and, when accumulated to high enough levels, is able to stimulate AMPK activity (Corton, J. M. *et.al.* Eur. J. Biochem. 229: 558 (1995)). However, ZMP also acts as an AMP mimic in the regulation of other enzymes, and is therefore

not a specific AMPK activator (Musi, N. and Goodyear, L. J. Current Drug Targets--Immune, Endocrine and Metabolic Disorders 2:119 (2002)).

[0036] The disclosure provides methods for stimulating a particular cycle of the circadian clock in a subject by either using an AMPK agonist or AMPK antagonist. In one embodiment, an AMPK agonist is used to promote a circadian cycle associated with increased CLOCK/BMAL1 transcriptional activity. In one embodiment the AMPK agonist promotes a sleep effect due to signaling of energy conservation through the corresponding kinase cascade. The method includes administering to a subject an AMPK agonist in an amount sufficient to simulate an energy deficient state in a subject. By "energy deficient state" refers to a state in which the γ subunit of AMPK undergoes a conformation change. Promoting a sleep effect means that such effect is improved in a subject more than would have occurred in the absence of an AMPK agonist.

[0037] The disclosed methods envision the use of any method of administration, dosage, and/or formulation of an AMPK agonist alone or in combination with other circadian regulating agents or sleep aids that have the desired outcome of inducing a desired state of the circadian cycle in a subject receiving the formulation, including, without limitation, methods of administration, dosages, and formulations well known to those of ordinary skill in the pharmaceutical arts.

[0038] AMPK agonist of the disclosure may be administered in the form of a drug to a human or an animal. Alternatively, the AMPK agonist may be incorporated into a variety of foods and beverages or pet foods so as to be consumed by humans or animals. The AMPK agonist may be applied to a common food or beverage, or may be applied to a functional food or beverage, a food for a subject suffering a disease, or a food for specified health use, the food (or beverage) bearing a label thereon indicating that it has a physiological function; for example, sleep aid.

[0039] The AMPK agonist alone or in combination with other sleep aid or active ingredients may be formulated into a drug

product; for example, a peroral solid product such as a tablet or a granule, or a peroral liquid product such as a solution or a syrup.

[0040] Modes of administering an AMPK agonist or a formulation in the disclosed method include, but are not limited to, intrathecal, intradermal, intramuscular, intraperitoneal (ip), intravenous (iv), subcutaneous, intranasal, epidural, intradural, intracranial, intraventricular, and oral routes. In a specific example, the AMPK agonist is administered orally. Other convenient routes for administration of an AMPK agonist include for example, infusion or bolus injection, topical, absorption through epithelial or mucocutaneous linings (for example, oral mucosa, rectal and intestinal mucosa, and the like) ophthalmic, nasal, and transdermal. Administration can be systemic or local. Pulmonary administration also can be employed (for example, by an inhaler or nebulizer), for instance using a formulation containing an aerosolizing agent.

[0041] As described more fully below, the AMPK agonist may be administered orally, parenterally, intramuscularly, intravascularly or by any appropriate route. In one embodiment, the AMPK agonist is administered epidurally. In one embodiment, the AMPK agonist is formulated to promote crossing of the blood-brain barrier.

[0042] In specific embodiments, it may be desirable to administer an AMPK agonist locally. This may be achieved by, for example, local or regional infusion or perfusion, topical application (for example, wound dressing), injection, catheter, suppository, or implant (for example, implants formed from porous, non-porous, or gelatinous materials, including membranes, such as sialastic membranes or fibers), and the like.

[0043] It should be recognized that in addition to use of agonist, antagonist may also be used to stimulate a waking state. The disclosure also provide methods of promoting an active state comprising administering an agent that antagonizes an AMPK activity thereby setting the metabolism and activity to a "wake" or "active" cycle. In one embodiment, the AMPK antagonist is an inhibitory antibody. In one embodiment, the AMPK antagonist is a small molecule inhibitors such as Compound C (Dorsomorphin, 6-[4-(2-

Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo[1,5-a]-pyrimidine), analog, derivative or salt thereof.

[0044] In other embodiments, a pump (such as a transplanted minipump) may be used to deliver an AMPK agonist or a formulation (see, e.g., Langer *Science* 249, 1527, 1990; Sefton *Crit. Rev. Biomed. Eng.* 14, 201, 1987; Buchwald *et al.*, *Surgery* 88, 507, 1980; Saudek *et al.*, *N. Engl. J. Med.* 321, 574, 1989). In another embodiment, an AMPK agonist or a formulation is delivered in a vesicle, in particular liposomes (see, e.g., Langer, *Science* 249, 1527, 1990; Treat *et al.*, in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, N. Y., pp. 353-365, 1989).

[0045] In yet another embodiment, an AMPK agonist can be delivered in a controlled-release formulation. Controlled-release systems, such as those discussed in the review by Langer (*Science* 249, 1527 1990), are known. Similarly, polymeric materials useful in controlled-released formulations are known (see, e.g., Ranger *et al.*, *Macromol. Sci. Rev. Macromol. Chem.* 23, 61, 1983; Levy *et al.*, *Science* 228, 190, 1985; During *et al.*, *Ann. Neurol.* 25, 351, 1989; Howard *et al.*, *J. Neurosurg.* 71, 105, 1989). For example, an agonist may be coupled to a class of biodegradable polymers useful in achieving controlled release of a compound, including polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

[0046] The disclosed methods contemplate the use of any dosage form of an AMPK agonist or formulation thereof that delivers the agonist(s) and achieves a desired result. Dosage forms are commonly known and are taught in a variety of textbooks, including for example, Allen *et al.*, *Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems*, Eighth Edition, Philadelphia, PA:Lippincott Williams & Wilkins, 2005, 738 pages. Dosage forms for use in a disclosed method include, without limitation, solid dosage forms and solid modified-release drug delivery systems (e.g., powders and granules, capsules, and/or tablets); semi-solid dosage forms and

transdermal systems (e.g., ointments, creams, and/or gels); transdermal drug delivery systems; pharmaceutical inserts (e.g., suppositories and/or inserts); liquid dosage forms (e.g., solutions and disperse systems); and/or sterile dosage forms and delivery systems (e.g., parenterals, and/or biologics). Particular exemplary dosage forms include aerosol (including metered dose, powder, solution, and/or without propellants); beads; capsule (including conventional, controlled delivery, controlled release, enteric coated, and/or sustained release); caplet; concentrate; cream; crystals; disc (including sustained release); drops; elixir; emulsion; foam; gel (including jelly and/or controlled release); globules; granules; gum; implant; inhalation; injection; insert (including extended release); liposomal; liquid (including controlled release); lotion; lozenge; metered dose (e.g., pump); mist; mouthwash; nebulization solution; ocular system; oil; ointment; ovules; powder (including packet, effervescent, powder for suspension, powder for suspension sustained release, and/or powder for solution); pellet; paste; solution (including long acting and/or reconstituted); strip; suppository (including sustained release); suspension (including lente, ultre lente, reconstituted); syrup (including sustained release); tablet (including chewable, sublingual, sustained release, controlled release, delayed action, delayed release, enteric coated, effervescent, film coated, rapid dissolving, slow release); transdermal system; tincture; and/or wafer. Typically, a dosage form is a formulation of an effective amount (such as a therapeutically effective amount) of at least one active pharmaceutical ingredient including an AMPK agonist with pharmaceutically acceptable excipients and/or other components (such as one or more other active ingredients). An aim of a drug formulation is to provide proper administration of an active ingredient (such as an AMPK agonist or AMPK antagonist) to a subject. A formulation should suit the mode of administration. The term "pharmaceutically acceptable" means approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use

in animals, and, more particularly, in humans. Excipients for use in exemplary formulations include, for instance, one or more of the following: binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, colorings, preservatives, diluents, adjuvants, and/or vehicles. In some instances, excipients collectively may constitute about 5%-95% of the total weight (and/or volume) of a particular dosage form.

[0047] Pharmaceutical excipients can be, for instance, sterile liquids, such as water and/or oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water is an exemplary carrier when a formulation is administered intravenously. Saline solutions, blood plasma medium, aqueous dextrose, and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Oral formulations can include, without limitation, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. A more complete explanation of parenteral pharmaceutical excipients can be found in Remington, The Science and Practice of Pharmacy, 19th Edition, Philadelphia, PA:Lippincott Williams & Wilkins, 1995, Chapter 95. Excipients may also include, for example, pharmaceutically acceptable salts to adjust the osmotic pressure, lipid carriers such as cyclodextrins, proteins such as serum albumin, hydrophilic agents such as methyl cellulose, detergents, buffers, preservatives and the like. Other examples of pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, and the like. A formulation, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.

[0048] In some embodiments involving oral administration, oral dosages of an AMPK agonist will generally range between about 0.001 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day, and such as about 0.01-10 mg/kg/day (unless specified otherwise, amounts of active ingredients are on the basis of a

neutral molecule, which may be a free acid or free base). For example, an 80 kg subject would receive between about 0.08 mg/day and 8 g/day, such as between about 0.8 mg/day and 800 mg/day. A suitably prepared medicament for once a day administration would thus contain between 0.08 mg and 8 g, such as between 0.8 mg and 800 mg. In some instance, formulation comprising an AMPK agonist or antagonist may be administered in divided doses of two, three, or four times daily. For administration twice a day, a suitably prepared medicament as described above would contain between 0.04 mg and 4 g, such as between 0.4 mg and 400 mg. Dosages outside of the aforementioned ranges may be necessary in some cases. Examples of daily dosages that may be given in the range of 0.08 mg to 8 g per day include 0.1 mg, 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, 1 g, 2 g, 4 g and 8 g. These amounts can be divided into smaller doses if administered more than once per day (e.g., one-half the amount in each administration if the drug is taken twice daily).

[0049] For some method embodiments involving administration by injection (e.g., intravenously or subcutaneous injection), a subject would receive an injected amount that would deliver the active ingredient in approximately the quantities described above. The quantities may be adjusted to account for differences in delivery efficiency that result from injected drug forms bypassing the digestive system. Such quantities may be administered in a number of suitable ways, e.g. large volumes of low concentrations of active ingredient during one extended period of time or several times a day, low volumes of high concentrations of active ingredient during a short period of time, e.g. once a day. Typically, a conventional intravenous formulation may be prepared which contains a concentration of active ingredient of between about 0.01-1.0 mg/ml, such as for example 0.1 mg/ml, 0.3 mg/ml, or 0.6 mg/ml, and administered in amounts per day equivalent to the amounts per day stated above. For example, an 80 kg subject, receiving 8 ml twice a day of an intravenous formulation having a concentration of active ingredient of 0.5 mg/ml, receives 8 mg of active ingredient per day.

[0050] In other embodiments, an AMPK agonist or antagonist (or a formulation thereof) can be administered at about the same dose throughout a treatment period, in an escalating dose regimen, or in a loading-dose regime (for example, in which the loading dose is about two to five times a maintenance dose). In some embodiments, the dose is varied during the course of usage based on the condition of the subject receiving the composition, the apparent response to the composition, and/or other factors as judged by one of ordinary skill in the art. In some embodiments long-term administration of an AMPK agonist or antagonist is contemplated, for instance to manage chronic insomnia or sleep-wake cycle disorders.

[0051] The disclosure also provides methods of screening for agents that modulate circadian rhythm by measuring AMPK activation or inhibition. The methods for screening for a compound that modulates circadian rhythm involve providing a cell, tissue or subject (e.g., an animal) comprising an AMPK pathway; contacting the subject with an agent suspected of having circadian rhythm modulating activity and measuring the effect on AMPK activity either directly or via downstream kinase activity. The test agent can be provided to a cell preparation, tissue, organ, organism or animal that has at least one observable index of circadian rhythm function and expresses an AMPK. The ability of the agent to modulate circadian rhythm can be tested in a variety of animal species that exhibit indicia of circadian rhythm function, as well as organs, tissues, and cells obtained from such animals, and cell preparations derived therefrom. An agent that modulates AMPK activity can then be identified as an agent that has putative circadian rhythm modulating activity.

[0052] A variety of *in vitro* screening methods are useful for identifying an antagonist or agonist that modulates circadian rhythm. The ability of a compound to modulate AMPK can be indicated, for example, by the ability of the compound to bind to and activate or inactivate AMPK, block downstream kinase activity, modulate phosphorylation and dephosphorylation, or modulate a predetermined signal produced by AMPK. Therefore, signaling and

binding assays can be used to identify an antagonist or agonist of AMPK that is provided in the methods of the disclosure for identifying a compound that modulates circadian rhythm.

[0053] An "agent" is any substance or any combination of substances that is useful for achieving an end or result; for example, a substance or combination of substances useful for modulating a protein activity associated with AMPK activation cascade (e.g., AMPK-dependent phosphorylation event), or useful for modifying or affecting a protein-protein interaction or ATP metabolism.

[0054] Exemplary agents include, but are not limited to, peptides such as, for example, soluble peptides, including but not limited to, members of random peptide libraries (see, e.g., Lam *et al.*, *Nature*, 354:82-84, 1991; Houghten *et al.*, *Nature*, 354:84-86, 1991), and combinatorial chemistry-derived molecular library made of D- and/or L-configuration amino acids, phosphopeptides (including, but not limited to, members of random or partially degenerate, directed phosphopeptide libraries; see, e.g., Songyang *et al.*, *Cell*, 72:767-778, 1993), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and Fab, F(ab')₂ and Fab expression library fragments, and epitope-binding fragments thereof), small organic or inorganic molecules (such as, so-called natural products or members of chemical combinatorial libraries), molecular complexes (such as protein complexes), or nucleic acids.

[0055] Libraries (such as combinatorial chemical libraries) useful in the disclosed methods include, but are not limited to, peptide libraries (see, e.g., U.S. Pat. No. 5,010,175; Furka, *Int. J. Pept. Prot. Res.*, 37:487-493, 1991; Houghton *et al.*, *Nature*, 354:84-88, 1991; PCT Publication No. WO 91/19735), encoded peptides (e.g., PCT Publication WO 93/20242), random bio-oligomers (e.g., PCT Publication No. WO 92/00091), benzodiazepines (e.g., U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:6909-6913, 1993), vinylogous polypeptides (Hagihara *et al.*, *J. Am. Chem. Soc.*, 114:6568, 1992), nonpeptidal peptidomimetics with glucose

scaffolding (Hirschmann *et al.*, J. Am. Chem. Soc, 114:9217-9218, 1992), analogous organic syntheses of small compound libraries (Chen *et al.*, J. Am. Chem. Soc, 116:2661, 1994), oligocarbamates (Cho *et al.*, Science, 261: 1303, 1003), and/or peptidyl phosphonates (Campbell *et al.*, J. Org. Chem., 59:658, 1994), nucleic acid libraries (see Sambrook *et al.* Molecular Cloning, A Laboratory Manual, Cold Springs Harbor Press, N. Y., 1989; Ausubel *et al.*, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y., 1989), peptide nucleic acid libraries (see, *e.g.*, U.S. Pat. No. 5,539,083), antibody libraries (see, *e.g.*, Vaughn *et al.*, Nat. Biotechnol, 14:309-314, 1996; PCT App. No. PCT/US96/10287), carbohydrate libraries (see, *e.g.*, Liang *et al.*, Science, 274:1520-1522, 1996; U.S. Pat. No. 5,593,853), small organic molecule libraries (see, *e.g.*, benzodiazepines, Baum, C&EN, Jan 18, page 33, 1993; isoprenoids, U.S. Pat. No. 5,569,588; thiazolidionones and methathiazones, U.S. Pat. No. 5,549,974; pyrrolidines, U.S. Pat. Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Pat. No. 5,506,337; benzodiazepines, 5,288,514) and the like.

[0056] Libraries useful for the disclosed screening methods can be produce in a variety of manners including, but not limited to, spatially arrayed multipin peptide synthesis (Geysen, *et al.*, Proc Natl. Acad. Sci., 81(13):3998-4002, 1984), "tea bag" peptide synthesis (Houghten, Proc Natl. Acad. Sci., 82(15):5131-5135, 1985), phage display (Scott and Smith, Science, 249:386-390, 1990), spot or disc synthesis (Dittrich *et al.*, Bioorg. Med. Chem. Lett., 8(17):2351-2356, 1998), or split and mix solid phase synthesis on beads (Furka *et al.*, Int. J. Pept. Protein Res., 37(6):487-493, 1991; Lam *et al.*, Chem. Rev., 97 (2):411-448, 1997). Libraries may include a varying number of compositions (members), such as up to about 100 members, such as up to about 1000 members, such as up to about 5000 members, such as up to about 10,000 members, such as up to about 100,000 members, such as up to about 500,000 members, or even more than 500,000 members.

[0057] In one embodiment, high throughput screening methods involve providing a combinatorial chemical or peptide library

containing a large number of potential therapeutic compounds (e.g., effectors of AMPK protein-protein interactions). Such combinatorial libraries are then screened in one or more assays as described herein to identify those library members (particularly chemical species or subclasses) that display a desired characteristic activity (such as increasing or decreasing an AMPK protein-protein interaction). The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics. In some instances, pools of candidate agents may be identified and further screened to determine which individual or subpools of agents in the collective have a desired activity. Agents that affect (e.g., increase or decrease) an AMPK interaction or AMP-dependent phosphorylation of processes may have the effect of modulating circadian rhythms (e.g., sleep behaviour) in a subject and, therefore, are desirable to identify.

[0058] In screening methods described here, tissue samples, isolated cells, isolated polypeptides, and/or test agents can be presented in a manner suitable for high-throughput screening; for example, one or a plurality of isolated tissue samples, isolated cells, or isolated polypeptides can be inserted into wells of a microtitre plate, and one or a plurality of test agents can be added to the wells of the microtitre plate. Alternatively, one or a plurality of test agents can be presented in a high-throughput format, such as in wells of microtitre plate (either in solution or adhered to the surface of the plate), and contacted with one or a plurality of isolated tissue samples, isolated cells, and/or isolated polypeptides under conditions that, at least, sustain the tissue sample or isolated cells or a desired polypeptide function and/or structure. Test agents can be added to tissue samples, isolated cells, or isolated polypeptides at any concentration that is not lethal to tissues or cells, or does not have an adverse effect on polypeptide structure and/or function. It is expected that different test agents will have different effective concentrations. Thus, in some methods, it is advantageous to test a range of test agent concentrations.

[0059] Methods for detecting protein phosphorylation are conventional (see, e.g., Gloffke, *The Scientist*, 16(19):52, 2002; Screaton *et al.*, *Cell*, 119:61-74, 2004) and detection kits are available from a variety of commercial sources (see, e.g., Upstate (Charlottesville, VA, USA), Bio-Rad (Hercules, CA, USA), Marligen Biosciences, Inc. (Ijamsville, MD, USA), Calbiochem (San Diego, CA, USA). Briefly, phosphorylated protein can be detected using stains specific for phosphorylated proteins in gels. Alternatively, antibodies specific phosphorylated proteins can be made or commercially obtained. Antibodies specific for phosphorylated proteins can be, among other things, tethered to the beads (including beads having a particular color signature) or used in ELISA or Western blot assays.

[0060] In particular methods, the phosphorylation of a polypeptide is increased when such posttranslational modification is detectably measured or when such posttranslational modification is at least 20%, at least 30%, at least 50%, at least 100% or at least 250% higher than control measurements (e.g., in the same test system prior to addition of a test agent, or in a comparable test system in the absence of a test agent, or in a comparable test system in the absence of AMPK).

[0061] The amino acid sequences of prototypical AMPK subunits (such as AMPK α 1 and/or AMPK α 2) (and nucleic acids sequences encoding prototypical AMPK subunits (such as AMPK α 1 and/or AMPK α 2)) are well known. Exemplary AMPK α 1 amino acid sequences and the corresponding nucleic acid sequences are described, for instance, in GenBank Accession Nos. NM_206907.3 (GI:94557298) (Homo sapiens transcript variant 2 REFSEQ including amino acid and nucleic acid sequences); NM_006251.5 (GI:94557300) (Homo sapiens transcript variant 1 REFSEQ including amino acid and nucleic acid sequences); NM_001013367.3 (GI:94681060) (Mus musculus REFSEQ including amino acid and nucleic acid sequences); NMJ01039603.1 (GI:88853844) (Gallus gallus REFSEQ including amino acid and nucleic acid sequences); and NM_019142.1 (GI: 11862979XRaJfWS norvegicus REFSEQ including amino acid and nucleic acid sequences). Exemplary AMPK α 2 amino acid sequences and the corresponding nucleic acid

sequences are described, for instance, in GenBank Accession Nos. NM_006252.2 (GI:46877067) (Homo sapiens REFSEQ including amino acid and nucleic acid sequences); NM_178143.1 (GI:54792085) (Mus musculus REFSEQ including amino acid and nucleic acid sequences); NM_001039605.1 (GI:88853850) (Gallus gallus REFSEQ including amino acid and nucleic acid sequences); and NM_214266.1 (GI:47523597) (Mus musculus REFSEQ including amino acid and nucleic acid sequences).

[0062] In some method embodiments, a homolog or functional variant of an AMPK subunit shares at least 60% amino acid sequence identity with a prototypical AMPK α 1 and/or AMPK α 2 polypeptide; for example, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% amino acid sequence identity with an amino acid sequence as set forth in the GenBank Accession Nos. NM_206907.3; NM_006251.5; NM_01013367.3; NM_001039603.1; NM_019142.1; NM_006252.2; NM_178143.1; NM_001039605.1; or NM_214266.1. In other method embodiments, a homolog or functional variant of an AMPK subunit has one or more conservative amino acid substitutions as compared to a prototypical AMPK α 1 and/or AMPK α 2 polypeptide; for example, no more than 3, 5, 10, 15, 20, 25, 30, 40, or 50 conservative amino acid changes compared to an amino acid sequence as set forth in as set forth in GenBank Accession Nos. NM_206907.3; NM_006251.5; NM_01013367.3; NM_001039603.1; NM_019142.1; NM_006252.2; NM_178143.1; NM_001039605.1; or NM_214266.1. Exemplary conservative amino acid substitutions have been previously described herein.

[0063] Some method embodiments involve a functional fragment of AMPK or a subunit thereof (such as AMPK α 1 and/or AMPK α 2). Functional fragments of AMPK or a subunit thereof (such as AMPK α 1 and/or AMPK α 2) can be any portion of a full-length or intact AMPK polypeptide complex or subunit thereof (such as AMPK α 1 and/or AMPK α 2), including, e.g., about 20, about 30, about 40, about 50, about 75, about 100, about 150 or about 200 contiguous amino acid residues of same; provided that the fragment retains at least one AMPK (or AMPK α 1 and/or AMPK α 2) function of interest. Protein-protein interactions between polypeptides in an AMPK pathway are believed

to involve, at least, an AMPK α subunit (such as AMPK α 1 and/or AMPK α 2).

[0064] An "isolated" biological component (such as a polynucleotide, polypeptide, or cell) has been purified away from other biological components in a mixed sample (such as a cell or tissue extract). For example, an "isolated" polypeptide or polynucleotide is a polypeptide or polynucleotide that has been separated from the other components of a cell in which the polypeptide or polynucleotide was present (such as an expression host cell for a recombinant polypeptide or polynucleotide).

[0065] The term "purified" refers to the removal of one or more extraneous components from a sample. For example, where recombinant polypeptides are expressed in host cells, the polypeptides are purified by, for example, the removal of host cell proteins thereby increasing the percent of recombinant polypeptides in the sample. Similarly, where a recombinant polynucleotide is present in host cells, the polynucleotide is purified by, for example, the removal of host cell polynucleotides thereby increasing the percent of recombinant polynucleotide in the sample.

[0066] Isolated polypeptides or nucleic acid molecules, typically, comprise at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or even over 99% (w/w or w/v) of a sample.

[0067] Polypeptides and nucleic acid molecules are isolated by methods commonly known in the art and as described herein. Purity of polypeptides or nucleic acid molecules may be determined by a number of well-known methods, such as polyacrylamide gel electrophoresis for polypeptides, or agarose gel electrophoresis for nucleic acid molecules.

[0068] The similarity between two nucleic acid sequences or between two amino acid sequences is expressed in terms of the level of sequence identity shared between the sequences. Sequence identity is typically expressed in terms of percentage identity; the higher the percentage, the more similar the two sequences.

[0069] Methods for aligning sequences for comparison are well known in the art. Various programs and alignment algorithms are

described in: Smith and Waterman, *Adv. Appl. Math.* 2:482, 1981; Needleman and Wunsch, *J. Mol. Biol.* 48:443, 1970; Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444, 1988; Higgins and Sharp, *Gene* 73:237-244, 1988; Higgins and Sharp, *CABIOS* 5:151-153, 1989; Corpet *et al.*, *Nucleic Acids Research* 16:10881-10890, 1988; Huang, *et al.*, *Computer Applications in the Biosciences* 8:155-165, 1992; Pearson *et al.*, *Methods in Molecular Biology* 24:307-331, 1994; Tatiana *et al.*, (1999), *FEMS Microbiol. Lett.*, 174:247-250, 1999. Altschul *et al.* present a detailed consideration of sequence alignment methods and homology calculations (*J. Mol. Biol.* 215:403-410, 1990). The National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST™, Altschul *et al.*, *J. Mol. Biol.* 215:403-410, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and on the Internet, for use in connection with the sequence-analysis programs *blastp*, *blastn*, *blastx*, *tblastn* and *tblastx*. A description of how to determine sequence identity using this program is available on the internet under the help section for BLAST™.

[0070] For comparisons of amino acid sequences of greater than about 30 amino acids, the "Blast 2 sequences" function of the BLAST™ (*Blastp*) program is employed using the default BLOSUM62 matrix set to default parameters (cost to open a gap [default = 5]; cost to extend a gap [default = 2]; penalty for a mismatch [default = -3]; reward for a match [default = 1]; expectation value (E) [default = 10.0]; word size [default = 3]; number of one-line descriptions (V) [default = 100]; number of alignments to show (B) [default = 100]). When aligning short peptides (fewer than around 30 amino acids), the alignment should be performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins with even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method.

[0071] For comparisons of nucleic acid sequences, the "Blast 2 sequences" function of the BLAST™ (*Blastn*) program is employed using the default BLOSUM62 matrix set to default parameters (cost

to open a gap [default = 11]; cost to extend a gap [default = 1]; expectation value (E) [default = 10.0]; word size [default = 11]; number of one-line descriptions (V) [default = 100]; number of alignments to show (B) [default = 100]). Nucleic acid sequences with even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method.

[0072] Specific binding refers to the particular interaction between one binding partner (such as a binding agent) and another binding partner (such as a target). Such interaction is mediated by one or, typically, more noncovalent bonds between the binding partners (or, often, between a specific region or portion of each binding partner). In contrast to non-specific binding sites, specific binding sites are saturable. Accordingly, one exemplary way to characterize specific binding is by a specific binding curve. A specific binding curve shows, for example, the amount of one binding partner (the first binding partner) bound to a fixed amount of the other binding partner as a function of the first binding partner concentration. As the first binding partner concentration increases under these conditions, the amount of the first binding partner bound will saturate. In another contrast to non-specific binding sites, specific binding partners involved in a direct association with each other (e.g., a protein-protein interaction) can be competitively removed (or displaced) from such association (e.g., protein complex) by excess amounts of either specific binding partner. Such competition assays (or displacement assays) are very well known in the art.

[0073] The disclosure also provides methods for identifying agents and agents useful for effecting circadian rhythms and sleep behaviour.

EXAMPLES

[0074] The following examples are provided to illustrate certain particular features and/or embodiments. These examples should not be construed to limit the invention to the particular features or embodiments described.

Example 1

[0075] **AMPK Contributes to Metabolic Alteration of Circadian Rhythms in Fibroblasts.** Given the importance of feeding-derived signals for circadian clock resetting, the regulation of AMPK by glucose availability, and the accumulating evidence of a role for AMPK in cryptochrome destabilization, the effects of AMPK expression and glucose availability were examined on circadian rhythmicity in fibroblasts. When wild type fibroblasts were cultured in medium containing limiting glucose, the amplitude of circadian *rev* and *dbp* expression was significantly enhanced (Fig. 1A and Fig. 4), consistent with a model in which glucose deprivation activates AMPK and reduces CRY stability, leading to de-repression of the CLOCK:BMAL1 targets *rev* and *dbp*. As predicted, addition of AICAR to the culture media mimicked the effects of glucose deprivation. Strikingly, neither glucose deprivation nor AICAR treatment affected the expression of *rev* and *dbp* in MEFs lacking AMPK (*ampk1*^{-/-};*ampk2*^{-/-}, "AMPK^{-/-}") (Fig. 1A and Fig. 4), indicating that the effects of glucose limitation on fibroblast circadian rhythms are mediated by AMPK.

[0076] The *Bmal1* promoter is repressed by REVERB α . Therefore, the effects of reducing glucose availability on circadian rhythms was examined using fibroblasts stably expressing luciferase under the control of a *Bmal1* promoter. Under standard (high glucose) culture conditions, high-amplitude circadian rhythms of expression of *Bmal1*-luciferase were observed with a period of 25.3 hours (Fig. 1B, C). Decreasing the amount of glucose in the culture media increased the circadian period up to 30.7 hours. When the *Bmal1*-luciferase expressing cells were cultured in high glucose medium supplemented with AICAR, the circadian period was similar to that observed in low glucose, reinforcing the idea that the circadian effects of glucose deprivation are mediated by AMPK. The increased expression of REVERB α observed under conditions of limited glucose is expected to result in decreased expression of genes that are repressed by REVERB α , including *Bmal1*. Indeed, activation of AMPK, either by decreasing glucose concentration or by AICAR treatment, decreased the amplitude of *Bmal1*-luciferase expression (Fig. 1D). Together, these results indicate that the circadian rhythms of

cultured fibroblasts are responsive to alterations in glucose availability and that these effects are mediated by AMPK-directed phosphorylation.

[0077] Circadian Regulation of AMPK *in vivo*. To investigate the diurnal regulation of AMPK, AMPK transcription, localization, and substrate phosphorylation was examined in peripheral organs of intact animals. All experiments were performed using animals maintained in constant darkness following entrainment to a standard light:dark cycle to ensure that the observed effects were circadian rather than diurnal responses to alterations in the external environment.

[0078] The phosphorylation of both AMPK substrates examined, ACC1-Ser79 and Raptor-Ser792, was reproducibly higher during the subjective day than at night (Fig. 2A), approximately corresponding to the time of day at which negative feedback proteins are unstable, consistent with a model in which rhythmic AMPK activation contributes to the degradation. While exploring the circadian regulation of AMPK in mouse liver, a robust circadian expression of the regulatory *ampk β 2* subunit (Fig. 2B), with peak expression concurrent with the time of minimal nuclear cryptochrome proteins (Fig. 2C). AMPK β 2 has been reported to drive the nuclear localization of AMPK complexes, while AMPK β 1-containing complexes are targeted to the plasma membrane. Thus, the circadian transcription of *ampk β 2* suggests that oscillating AMPK β 2 diurnally regulates the nuclear localization of AMPK α 1 and AMPK α 2. To test this hypothesis, the protein levels of AMPK α 1 and AMPK α 2 in liver nuclei collected across the circadian cycle were measured (Fig. 2C) and observed rhythmicity of nuclear AMPK α 1, peaking synchronously with *ampk β 2* expression. AMPK α 2 contains a nuclear localization signal and was consistently present in the nucleus. The time of peak AMPK α 1 nuclear localization is also the time of minimum CRY1 protein in liver nuclei, suggesting that rhythmic nuclear import of AMPK may contribute to the AMPK-mediated phosphorylation and degradation of cryptochromes.

[0079] AMPK Alters Circadian Clocks *In vivo*. Genetic deletion of both AMPK α 1 and AMPK α 2 in mice leads to early embryonic

lethality. Therefore, to further explore the role of AMPK in the liver circadian clock, circadian proteins and transcripts were examined over twenty-four hours in the livers of control mice (*LKB1*^{+/+}) or littermates harboring loss of *lkb1* in hepatocytes (*LKB1*^{L/L}) housed in constant darkness following entrainment to a light:dark cycle. Liver-specific deletion of *lkb1* abolishes AMPK activation in that organ and significantly increased the amount of CRY1 and CRY2 proteins present in liver nuclei across the circadian cycle, particularly during the daytime hours when AMPK was found to be most active in unaltered mice (Fig. 3B). This increase was associated with decreased REVERB α expression (Fig. 3B) in the period corresponding to daylight and decreased amplitude of circadian transcripts throughout the circadian cycle (Fig. 3C). Thus, loss of AMPK signaling *in vivo* stabilizes cryptochromes and disrupts circadian rhythms, establishing a mechanism of synchronization for light-independent peripheral circadian clocks.

[0080] While this disclosure has been described with an emphasis upon particular embodiments, it will be obvious to those of ordinary skill in the art that variations of the particular embodiments may be used and it is intended that the disclosure may be practiced otherwise than as specifically described herein. Accordingly, this disclosure includes all modifications encompassed within the spirit and scope of the disclosure as defined by the following claims:

We Claim:

1. Use of an AMP kinase agonist or antagonist for the manufacture of a medicament to modulate circadian rhythms in a subject.
2. The use of claim 1, wherein the AMPK agonist is selected from the group consisting of biguanide derivatives, AICAR, metformin or derivatives thereof, phenformin or derivatives thereof, leptin, adiponectin, AICAR (5-aminoimidazole-4-carboxamide, ZMP, DRL-16536, BG800 compounds (Betagenon), and furan-2-carboxylic acid derivative.
3. The use of claim 1, wherein the subject is a mammal.
4. The use of claim 1, wherein an effective amount is from about 0.5 mg/kg per day to about 100 mg/kg per day in a single dose or in divided doses.
5. The use of claim 1, wherein the compound is formulated for oral administration, intravenous injection, intramuscular injection, epidural delivery, intracranial, topically, intraocularly, as a suppository or subcutaneous injection.
6. A composition comprising an AMP kinase agonist and at least one other circadian rhythm modifying agent.
7. The composition of claim 6, wherein the at least one other circadian rhythm modifying agent is a sleep aid.
8. The composition of claim 6, wherein the AMPK agonist is selected from the group consisting of biguanide derivatives, AICAR, metformin or derivatives thereof, phenformin or derivatives thereof, leptin, adiponectin, AICAR (5-aminoimidazole-4-carboxamide, ZMP, DRL-16536, BG800 compounds (Betagenon), and furan-2-carboxylic acid derivative.
9. The composition of claim 6, wherein the compound is formulated for oral administration, intravenous injection, intramuscular injection, epidural delivery, intracranial delivery, topically, intraocularly, as a suppository or subcutaneous injection.

10. A method for modulating sleep in a mammal comprising, administering to the mammal an effective amount of an AMPK agonist to modulate circadian rhythms in a mammal.

11. The method of claim 10, wherein the mammal is a human.

12. The method of claim 10, wherein the circadian rhythm is sleep behavior.

13. A method for identifying an agent that modulates circadian rhythms or sleep in a subject, comprising:

(a) contacting a sample comprising a AMPK pathway with at least one test agent; and

(b) comparing an activity of the AMPK or AMPK pathway in the presence and absence of the test agent wherein a test agent the changes that activity is indicative of an agent that modulates circadian rhythm activity.

14. Use of a composition of claim 6, 7, or 8 to modulate circadian rhythms in a subject.

15. The use of claim 14, wherein the subject is a mammal.

16. The use of claim 14, wherein an effective amount is from about 0.5 mg/kg per day to about 100 mg/kg per day in a single dose or in divided doses.

17. The use of claim 14, wherein the compound is formulated for oral administration, intravenous injection, intramuscular injection, epidural delivery, intracranial, topically, intraocularly, as a suppository or subcutaneous injection.

1/4




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4